Xeris Biopharma Holdings Inc
XERS5.535USD
+0.155+2.88%
Market hours （ET）Quotes delayed by 15 min
863.54MMarket Cap
LossP/E TTM
More Details of Xeris Biopharma Holdings Inc Company
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.
Company Info
Ticker SymbolXERS
Company nameXeris Biopharma Holdings Inc
IPO dateJun 21, 2018
CEOMr. John P. Shannon
Number of employees394
Security typeOrdinary Share
Fiscal year-endJun 21
Address1375 West Fulton Street, Suite 1300
CityCHICAGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code60607
Phone18444455704
Websitehttps://www.xerispharma.com/
Ticker SymbolXERS
IPO dateJun 21, 2018
CEOMr. John P. Shannon
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
937.75K
+2.74%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
513.93K
+80.45%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
169.78K
+41.74%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
113.87K
+78.28%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
112.91K
+79.48%
Mr. Steven M. Pieper
Mr. Steven M. Pieper
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James Brady
Mr. James Brady
Independent Director
Independent Director
--
--
Mr. John P. Shannon
Mr. John P. Shannon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Allison Wey
Ms. Allison Wey
Senior Vice President - Investor Relations & Corporate Communications
Senior Vice President - Investor Relations & Corporate Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
937.75K
+2.74%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
513.93K
+80.45%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
169.78K
+41.74%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
113.87K
+78.28%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
112.91K
+79.48%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
By BusinessUSD
Name
Revenue
Proportion
Product revenue -Recorlev
25.53M
42.47%
Product revenue - Gvoke
20.84M
34.67%
Product revenue - Keveyis
11.43M
19.01%
Royalty, contract and other revenue
2.32M
3.85%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product revenue -Recorlev
25.53M
42.47%
Product revenue - Gvoke
20.84M
34.67%
Product revenue - Keveyis
11.43M
19.01%
Royalty, contract and other revenue
2.32M
3.85%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.99%
The Vanguard Group, Inc.
5.06%
Geode Capital Management, L.L.C.
2.13%
State Street Global Advisors (US)
2.08%
Morgan Stanley & Co. LLC
1.96%
Other
82.78%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.99%
The Vanguard Group, Inc.
5.06%
Geode Capital Management, L.L.C.
2.13%
State Street Global Advisors (US)
2.08%
Morgan Stanley & Co. LLC
1.96%
Other
82.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.15%
Investment Advisor/Hedge Fund
13.83%
Hedge Fund
13.12%
Research Firm
6.70%
Individual Investor
4.21%
Pension Fund
0.27%
Venture Capital
0.14%
Family Office
0.10%
Bank and Trust
0.09%
Other
41.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
335
93.79M
58.56%
+12.75M
2025Q1
335
93.86M
58.93%
+12.36M
2024Q4
297
71.87M
48.21%
-8.26M
2024Q3
280
71.79M
48.23%
-5.89M
2024Q2
269
66.65M
44.99%
-10.81M
2024Q1
284
69.70M
49.68%
-4.28M
2023Q4
271
65.59M
47.45%
-7.22M
2023Q3
264
62.48M
45.27%
-15.54M
2023Q2
276
65.86M
49.56%
-15.25M
2023Q1
284
62.09M
46.86%
-20.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
9.59M
5.99%
-94.01K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
8.11M
5.06%
+210.58K
+2.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.41M
2.13%
+54.40K
+1.62%
Mar 31, 2025
State Street Global Advisors (US)
3.33M
2.08%
-16.62K
-0.50%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.15M
1.96%
+2.62M
+494.91%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.05M
1.91%
+1.69M
+123.87%
Mar 31, 2025
Rosalind Advisors, Inc.
2.50M
1.56%
-609.01K
-19.61%
Mar 31, 2025
Millennium Management LLC
2.32M
1.45%
+369.42K
+18.96%
Mar 31, 2025
Nuveen LLC
2.22M
1.39%
+324.06K
+17.07%
Mar 31, 2025
Goldman Sachs & Company, Inc.
2.20M
1.37%
+1.12M
+103.68%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
iShares Micro-Cap ETF
0.16%
Federated Hermes MDT Small Cap Core ETF
0.14%
Principal U.S. Small-Cap ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.06%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.38%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.95%
iShares Micro-Cap ETF
Proportion0.16%
Federated Hermes MDT Small Cap Core ETF
Proportion0.14%
Principal U.S. Small-Cap ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.07%
Fidelity Enhanced Small Cap ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
